Zero Candida Co-Founder and CEO Eli Ben-Haroosh joined Steve Darling from Proactive to share with Proactive that the company has been granted a final patent in South Africa as part of its efforts to establish a global patent portfolio. Applications have also been filed in the United States, Brazil, and Europe. The company is developing an AI-driven smart tampon-like device that utilizes a therapeutic blue light with precise wavelength and intensity to achieve a 99.999% success rate in treating the Candida fungus overnight at the point of care.
This groundbreaking technology targets Vulvo-Vaginal Candidiasis, a condition affecting 75% of women worldwide, and offers a chemical-free treatment without side effects. Zero Candida’s innovative ZCT device is designed to bridge healthcare gaps, especially in underserved and developing regions. It enables hybrid medical services by collecting and transmitting treatment data to gynecologists in real time via a built-in Wi-Fi chip and VoIP, allowing for remote care, personalized treatment, and ongoing monitoring.
Ben-Haroosh emphasized that the device's combination of effectiveness, side-effect-free treatment, and seamless data integration responds to the growing demand for safer, non-invasive solutions in women’s health. The ZCT device represents a transformative step in accessible, high-tech gynecological care.